Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Companies Involved in Therapeutics Development
Baliopharm AG
CytImmune Sciences Inc
Eyevensys SAS
G&E Corp
GlaxoSmithKline Plc
Inflamalps SA
Inmune Bio Inc
Philogen SpA
Promethera Biosciences SA
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Drug Profiles
Atrosab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atrosab (improved formulation) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atrosimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYT-21625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daromun - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize TNFRSF1A for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EYS-606 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fibromun - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2862277 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INB-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Product Development Milestones
Featured News & Press Releases
Mar 19, 2019: INmune Bio co-founder and CEO presented at Cambridge Healthtech Institute’s 4th Annual Immuno-Oncology Summit Europe 2019
Feb 11, 2019: INmune Bio awarded a $1 million grant for the development of XPro1595 for the treatment of Alzheimers Disease
Dec 11, 2018: Study results presented at San Antonio Breast Cancer Symposium 2018
Nov 15, 2018: Data from University of Pittsburgh on INB03 for Treatment of Melanoma Presented at the 33rd Annual Society for Immunotherapy of Cancer (SITC) Meeting
Aug 09, 2018: Eyevensys appoints new Board member, Gerald Cagle
Jul 18, 2018: Philogen receives orphan drug desigtion for the treatment of melanoma
May 23, 2018: INmune Bio Initiates Phase I Clinical Trial of INB03
Mar 12, 2018: notechnology Delivers a Two-Punch Combition With Big Potential for Patients With Rare Cancers
Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma
May 09, 2017: Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases
Apr 20, 2017: Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development
Apr 11, 2017: Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development
Oct 28, 2016: Philogen Receives Orphan Drug Desigtion for the Treatment of Soft Tissue Sarcoma
May 31, 2016: Eyevensys appoints Dr. Patricia Zilliox, an Experienced Ophthalmology Clinical Development Leader, to Board of Directors
Feb 18, 2016: Eyevensys Receives Orphan Drug Desigtion in the European Union for EYS606 for the Non-Infectious Uveitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Baliopharm AG, H1 2019
Pipeline by CytImmune Sciences Inc, H1 2019
Pipeline by Eyevensys SAS, H1 2019
Pipeline by G&E Corp, H1 2019
Pipeline by GlaxoSmithKline Plc, H1 2019
Pipeline by Inflamalps SA, H1 2019
Pipeline by Inmune Bio Inc, H1 2019
Pipeline by Philogen SpA, H1 2019
Pipeline by Promethera Biosciences SA, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Discontinued Products, H1 2019